

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 July 2021 (22.07.2021)



(10) International Publication Number
WO 2021/146323 A1

(51) International Patent Classification:

C07K 14/705 (2006.01) C07K 16/10 (2006.01)
C07K 14/725 (2006.01)

(21) International Application Number:

PCT/US2021/013289

(22) International Filing Date:

13 January 2021 (13.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/960,613	13 January 2020 (13.01.2020)	US
62/968,954	31 January 2020 (31.01.2020)	US
62/977,023	14 February 2020 (14.02.2020)	US

(71) Applicant: CYTODYN INC. [US/US]; 1111 Main Street, Suite 660, Vancouver, Washington 98660 (US).

(72) Inventor: KELLY, Scott; c/o CytoDyn Inc., 1111 Main Street, Suite 660, Vancouver, Washington 98660 (US).

(74) Agent: EIDT, Chandra, E. et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CCR5 BINDING AGENT FOR TREATMENT OF CCR5 POSITIVE METASTATIC BREAST CANCER

CCR5 Cytoplasmic
Node-negative breast
cancer (537 patients)

Overall survival
P=0.0013

Teal – Low CCR5
Grey – High CCR5




Fig. 2

(57) Abstract: The present disclosure relates to the use of CCR5 binding agents, such as the leronlimab, in the treatment or prevention of CCR5+ metastatic cancer. Presented herein are methods for treating a subject for metastatic breast cancer by administering to the subject an effective amount of a CCR5 binding agent, such as leronlimab.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*